Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.

Autor: Desmet, Thomas, Julian, Elaine, Van Dyck, Walter, Huys, Isabelle, Simoens, Steven, Giuliani, Rosa, Toumi, Mondher, Dierks, Christian, Dierks, Juliana, Cardone, Antonella, Houÿez, Francois, Pavlovic, Mira, Berntgen, Michael, Mol, Peter, Schiel, Anja, Goettsch, Wim, Gianfrate, Fabrizio, Capri, Stefano, Ryan, James, Ducournau, Pierre

Publikováno v: Journal of Market Access & Health Policy; Mar2024, Vol. 12 Issue 1, p21-34, 14p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Additional file 1 of How can a joint European health technology assessment provide an ‘additional benefit’ over the current standard of national assessments?

Autor: Julian, Elaine, Gianfrate, Fabrizio, Sola-Morales, Oriol, Mol, Peter, Bergmann, Jean-François, Salmonson, Tomas, Hebborn, Ansgar, Grande, Mathilde, Ruof, Jörg

Additional file 1.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51c82ddb9eaee48dc4fceff7e2e2ac3e

The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire .

Autor: Van Haesendonck L; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Ruof J; r-connect Ltd, Basel, Switzerland.; Medical School of Hanover, Hanover, Germany., Desmet T; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; Healthcare Management Centre, Vlerick Business School, Brussels, Belgium., Van Dyck W; Healthcare Management Centre, Vlerick Business School, Brussels, Belgium., Simoens S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Huys I; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Giuliani R; Guy's and St Thomas' NHS Foundation Trust, London, UK., Toumi M; Faculty of Medicine, Public Health Department, Aix-Marseille University, Marseille, France., Dierks C; Dierks+Company, Berlin, Germany., Dierks J; Dierks+Company, Berlin, Germany., Cardone A; Cancer Patients Europe Brussels, Belgium., Houÿez F; European Organisation for Rare Diseases (EURORDIS), Paris, France., Pavlovic M; Medicines Development and Training (MDT) Services, Paris, France., Berntgen M; Scientific Evidence Generation department, European Medicines Agency (EMA), Amsterdam, The Netherlands., Mol PGM; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands., Schiel A; Norwegian Medicines Agency (NOMA), Oslo, Norway., Goettsch W; National Health Care Institute, Diemen, The Netherlands., Gianfrate F; University of Ferrara, Ferrara, Italy.; School of Economics and Management, Cattaneo-LIUC University, Castellanza, Italy., Capri S; Health Economics and Payer Evidence, Astra Zeneca, Cambridge, UK., Ryan J; Global Market Access & Pricing, Abbvie AG, Cham, Switzerland., Ducournau P; HiTT Foundation, International University of Catalonia-UIC, Barcelona, Spain., Solà-Morales O; Utrecht Centre for Pharmaceutical Policy, Division of Pharmacoepidemiology and Clinical Pharmacology, University of Utrecht, Utrecht, The Netherlands., Julian E; r-connect Ltd, Basel, Switzerland.

Publikováno v: Journal of market access & health policy [J Mark Access Health Policy] 2023 Jun 04; Vol. 11 (1), pp. 2217543. Date of Electronic Publication: 2023 Jun 04 (Print Publication: 2023).